Innocan Pharma Corporation (CSE:INNO) (FRA:IP4) has announced that its R&G Relief & Go CBD Spray product has successfully passed detailed safety assessment requirements of the European Parliament and the Council on Cosmetic Products.
The product also has received a Cosmetic Product Safety Report (CPSR) for product marketing in the EU, the company said in a statement Wednesday.
READ: Innocan Pharma announces publication of two scientific articles supporting its CLX therapy for COVID-19-infected lungs
Wholly-owned subsidiary Innocan Israel’s patent-pending unique formulation spray combines the known benefits of active ingredients such as menthol and camphor with CBD and magnesium (more than 40% in the formula) to help the body relax and recover for sport-performing professionals.
Innocan Pharma noted that Nir Avram, the subsidiary’s CTO, has over 30 years of experience as a senior consultant in the area of pharmaceuticals and cosmetics. Avram consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations, and synthesis of novel materials, in connection with start-ups and established companies.
Nir is vice president of research & development at Emilia Cosmetics Israel and Emilia Resources in the US. Prior to that, he was VP of R&D at Careline, a leading cosmetics and toiletries manufacturer, and a member of the pharmaceutical innovation team at Perrigo.
"We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product," said Innocan Pharma CEO Iris Bincovich. "This is a major accomplishment for our team and an exciting milestone of our future".
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham